IBIO — iBio, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1420720 ·
Last close
$0.75
Market Cap
$52.71M
52W High
$3.82
52W Low
$0.68
ADV30
671,336
Next earnings
—
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,075,000 — -8,338,000 -7,551,000 88,651,000 45,435,000 10,081,000
Jun 2026 0 — -6,377,000 -10,601,000 99,110,000 56,395,000 13,397,000
Mar 2026 0 — -8,365,000 -7,730,000 85,834,000 47,631,000 8,297,000
Dec 2025 0 — -9,445,000 -8,993,000 64,393,000 28,672,000 7,833,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-26,940,000
Investing CF
$-10,960,000
Financing CF
$55,224,000
CapEx
$-1,398,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.31
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-372,819,000
Inventory
—
Receivables
$1,249,000
ST Investments
$31,219,000
EBIT TTM
$-34,858,000
Pretax Income TTM
$-34,875,000
Interest Exp TTM
$17,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,075,000
EBITDA
$-31,925,000
Free Cash Flow
$-19,561,000
Enterprise Value
$-23,033,484
Total Cash
$76,654,000
Total Debt
$2,068,000
Shares Out
70,455,809
Trailing EPS
$-0.27
Book Value
$1.22
ROE
-51.8%
ROA
-26.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Jun 2026 100,000 -30,138,000 -33,044,000 99,110,000 13,397,000 85,713,000 -23,218,000
Jun 2025 400,000 -18,602,000 -18,377,000 23,185,000 8,305,000 14,880,000 -15,304,000
Jun 2024 225,000 -16,634,000 -24,907,000 28,734,000 7,410,000 21,324,000 -18,554,000
Jun 2023 0 -29,343,000 -65,010,000 41,207,000 25,826,000 15,381,000 -30,436,000
Jun 2022 — — — — — — —

TTM Snapshot

Revenues TTM
$100,000
NetIncome TTM
$-33,044,000
OpCashFlow TTM
—
Assets (Latest)
$85,834,000
Forward EPS
$-0.52

Peers — same industry

TickerNameMarket CapLastDaily %
GANX Gain Therapeutics, Inc. $52.54M $1.18 —
SPRO Spero Therapeutics, Inc. $52.51M $0.90 —
AZR Azora Therapeutics, Inc. (DE) $52.36M $3.66 —
XLO Xilio Therapeutics, Inc. $53.26M $7.54 —
IBO IMPACT BIOMEDICAL INC. $53.31M $6.17 —

News headlines (Yahoo Finance, 1h cache)

iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences
2026-11-16 21:30 · Yahoo
iBio Targets First-Quarter Myostatin Data, Activin E Dosing as It Advances Obesity Pipeline
2026-11-12 08:12 · Yahoo
iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
2026-11-10 21:30 · Yahoo
iBio to Participate in Upcoming Investor Conferences
2026-11-02 21:30 · Yahoo
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
2026-10-13 11:00 · Yahoo
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
2026-09-01 20:30 · Yahoo
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-08-28 11:00 · Yahoo
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
2026-07-01 11:00 · Yahoo
iBio to Participate in Upcoming Healthcare Investor Conferences
2026-06-02 20:01 · Yahoo
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-05-12 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.